{
    "title": "106_s2501",
    "content": "The \"Generic Pharmaceutical Access and Choice for Consumers Act of 2000\" encourages the use of generic drugs in various healthcare programs, including Medicare and Medicaid. It also emphasizes therapeutic equivalence requirements for generic drugs and promotes the preference for generic pharmaceuticals in the Medicare program. The \"Generic Pharmaceutical Access and Choice for Consumers Act of 2000\" promotes the preference for generic pharmaceuticals in the Medicare program. Congress finds that generic pharmaceuticals are therapeutically equivalent to brand-name drugs, providing a safe and cost-effective alternative. The market has become more competitive due to increased availability of generics, leading to significant cost savings for purchasers. Substituting generics for brand-name drugs could save $8-10 billion annually, with generics costing 25-60% less per prescription. Generic pharmaceuticals cost 25-60% less than brand-name drugs, saving $15 to $30 per prescription. The market share of generics has doubled in the last decade. The Act aims to reduce prescription drug costs for the government and beneficiaries by promoting the use of generic drugs and ensuring their therapeutic equivalence to brand-name drugs. The Act aims to determine the therapeutic equivalence of generic pharmaceuticals to brand-name drugs, promoting their use and reducing prescription drug costs. SEC. 247 encourages the use of generic drugs under the Public Health Service Act. The Public Health Service Act encourages the use of generic drugs in grants or contracts for healthcare services, with exceptions for specific orders by providers or individual requests. Generic drugs are defined as therapeutically equivalent to listed drugs approved by the FDA, while nongeneric drugs are those approved under a different section of the FDA Act. The amendment made by this section applies to drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act, effective for drugs furnished after the enactment of this Act. SEC. 102 amends Section 8902 of title 5, United States Code, to require carriers to provide, pay, or reimburse for generic prescription drugs, unless the nongeneric form is specifically ordered by the provider or requested by the individual. The amendment applies to drugs furnished during contract years starting on or after January 1, 2001. The Social Security Act is amended to define 'drugs' as the generic form unless the nongeneric form is specifically ordered by the provider or requested by the individual. This amendment applies to drugs furnished on or after the date of enactment, with an exception for Medicare+Choice plans starting on or after January 1, 2001. SEC. 104. APPLICATION TO MEDICAID PROGRAM. Amends the Social Security Act to require states to use generic forms of drugs unless specifically ordered by the provider or requested by the individual. Effective for drugs furnished under approved State plans on or after the enactment date. SEC. 105. APPLICATION TO INDIAN HEALTH SERVICE. Amends the Indian Health Care Improvement Act to encourage the use of generic drugs in providing health care items or services. The Indian Health Service must ensure prescriptions are filled with generic drugs unless specifically ordered by the provider or requested by the individual. Effective for drugs furnished on or after the enactment date. SEC. 106. APPLICATION TO VETERANS PROGRAMS. Amends title 38, United States Code to encourage the use of generic drugs when furnishing prescription drugs under this chapter. The Secretary must provide a generic form of the drug unless specifically ordered by the provider or requested by the individual. Effective for drugs furnished on or after the enactment date. SEC. 107. APPLICATION TO RECIPIENTS OF UNIFORMED SERVICES HEALTH CARE. The Secretary of Defense must ensure that health care providers furnish generic drugs whenever possible, unless specifically ordered by the provider or requested by the individual. Effective for drugs furnished on or after the enactment date. SEC. 108. APPLICATION TO FEDERAL PRISONERS. The Attorney General must ensure that generic drugs are provided to prisoners charged or convicted of offenses against the United States, unless specifically ordered by the prescribing provider or requested by the prisoner. Effective for drugs furnished on or after the enactment date. TITLE II--THERAPEUTIC EQUIVALENCE REQUIREMENTS FOR GENERIC DRUGS. SEC. 201. THERAPEUTIC EQUIVALENCE OF GENERIC DRUGS. Section 505(j) of the Federal Food, Drug, and Cosmetic Act is amended to require the Secretary to determine if an abbreviated new drug application is therapeutically equivalent to the listed drug before approval. Therapeutic equivalence is based on factors like active ingredients, dosage form, route of administration, strength, and standards. The amended Section 505(j) of the Federal Food, Drug, and Cosmetic Act requires the Secretary to determine therapeutic equivalence of an abbreviated new drug application to the listed drug before approval. Factors considered include active ingredients, dosage form, route of administration, strength, and standards. The new drug must meet bioequivalence standards and be therapeutically equivalent to the listed drug. The official name of each drug therapeutically equivalent to a new drug approved under this subsection in the preceding 30-day period will be listed. The amendments made by this section will take effect on the date of enactment of this Act. TITLE III--GENERIC PHARMACEUTICALS AND MEDICARE REFORM\n\nSENSE OF THE SENATE: Legislation should prioritize the safe and cost-effective use of generic pharmaceuticals in conjunction with adding a prescription drug benefit to the Medicare program."
}